StocksFundsScreenerSectorsWatchlists
MEDP

MEDP - Medpace Holdings Inc Stock Price, Fair Value and News

402.58USD+4.86 (+1.22%)Market Closed

Market Summary

MEDP
USD402.58+4.86
Market Closed
1.22%

MEDP Alerts

  • 4 major insider sales recently.

MEDP Stock Price

View Fullscreen

MEDP RSI Chart

MEDP Valuation

Market Cap

12.4B

Price/Earnings (Trailing)

43.79

Price/Sales (Trailing)

6.57

EV/EBITDA

33.45

Price/Free Cashflow

31.21

MEDP Price/Sales (Trailing)

MEDP Profitability

EBT Margin

17.80%

Return on Equity

50.6%

Return on Assets

17.07%

Free Cashflow Yield

3.2%

MEDP Fundamentals

MEDP Revenue

Revenue (TTM)

1.9B

Rev. Growth (Yr)

26.47%

Rev. Growth (Qtr)

1.2%

MEDP Earnings

Earnings (TTM)

282.8M

Earnings Growth (Yr)

14.02%

Earnings Growth (Qtr)

10.98%

Breaking Down MEDP Revenue

Last 7 days

3.4%

Last 30 days

-1.2%

Last 90 days

40.4%

Trailing 12 Months

112.4%

How does MEDP drawdown profile look like?

MEDP Financial Health

Current Ratio

0.64

MEDP Investor Care

Buy Backs (1Y)

0.94%

Diluted EPS (TTM)

8.88

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20231.6B1.7B1.8B1.9B
20221.2B1.3B1.4B1.5B
2021955.0M1.0B1.1B1.1B
2020891.1M882.0M896.1M925.9M
2019742.3M786.2M823.2M861.0M
2018492.6M556.5M625.2M704.6M
2017428.6M428.9M431.7M436.2M
2016374.7M390.3M406.0M421.6M
2015000359.1M
20140000
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Medpace Holdings Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 31, 2024
carley brian t
acquired
-
-
79.00
-
Mar 31, 2024
kraft robert o.
acquired
-
-
72.00
-
Mar 31, 2024
mccarthy cornelius p. iii
acquired
-
-
63.00
-
Mar 15, 2024
burwig susan e
sold
-41,106
403
-102
exec. vp, operations
Mar 14, 2024
keating ashley m.
sold
-102,468
409
-250
-
Mar 14, 2024
keating ashley m.
acquired
42,180
84.36
500
-
Mar 08, 2024
medpace investors, llc
sold
-10,217,800
408
-25,000
-
Mar 08, 2024
troendle august j.
sold
-10,217,800
408
-25,000
ceo
Mar 07, 2024
medpace investors, llc
sold
-30,805,500
410
-75,000
-
Mar 07, 2024
keating ashley m.
acquired
25,955
54.99
472
-

1–10 of 50

Which funds bought or sold MEDP recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 10, 2024
PARK AVENUE SECURITIES LLC
reduced
-1.5
208,000
902,000
0.01%
Apr 10, 2024
Banque Cantonale Vaudoise
sold off
-100
-300,000
-
-%
Apr 09, 2024
MASSMUTUAL TRUST CO FSB/ADV
added
2.99
7,348
27,886
-%
Apr 09, 2024
Rise Advisors, LLC
new
-
27,078
27,078
0.01%
Apr 09, 2024
MATHER GROUP, LLC.
new
-
21,151
21,151
-%
Apr 08, 2024
Westwind Capital
reduced
-29.97
-1,419,000
17,103,000
4.33%
Apr 05, 2024
LOS ANGELES CAPITAL MANAGEMENT LLC
added
2.49
27,361,900
105,259,000
0.36%
Apr 05, 2024
FIRST HAWAIIAN BANK
added
4.28
327,621
1,201,540
0.04%
Apr 05, 2024
GAMMA Investing LLC
added
43.27
29,894
60,218
0.01%
Apr 05, 2024
CWM, LLC
added
100
421,000
677,000
-%

1–10 of 48

Are Funds Buying or Selling MEDP?

Are funds buying MEDP calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own MEDP
No. of Funds

Unveiling Medpace Holdings Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Mar 08, 2024
troendle august j.
19.4%
6,071,852
SC 13D/A
Feb 28, 2024
troendle august j.
20.8%
6,496,852
SC 13D/A
Feb 13, 2024
vanguard group inc
8.33%
2,556,443
SC 13G/A
Feb 09, 2024
wasatch advisors lp
-
0
SC 13G/A
Jan 26, 2024
blackrock inc.
7.9%
2,417,994
SC 13G/A
Dec 05, 2023
troendle august j.
21.9%
6,810,606
SC 13D/A
Sep 22, 2023
troendle august j.
23.0%
7,135,606
SC 13D/A
Feb 09, 2023
vanguard group inc
8.67%
2,696,146
SC 13G/A
Feb 08, 2023
wasatch advisors inc
-
0
SC 13G/A
Jan 26, 2023
blackrock inc.
10.2%
3,163,001
SC 13G/A

Recent SEC filings of Medpace Holdings Inc

View All Filings
Date Filed Form Type Document
Apr 03, 2024
ARS
ARS
Apr 03, 2024
DEF 14A
DEF 14A
Apr 03, 2024
DEFA14A
DEFA14A
Apr 02, 2024
4
Insider Trading
Apr 02, 2024
4
Insider Trading
Apr 02, 2024
4
Insider Trading
Mar 29, 2024
8-K
Current Report
Mar 20, 2024
PRE 14A
PRE 14A
Mar 19, 2024
4
Insider Trading
Mar 18, 2024
4
Insider Trading

Peers (Alternatives to Medpace Holdings Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
180.5B
23.9B
-3.62% -2.41%
38.05
7.55
-10.33% -33.23%
42.5B
6.7B
-1.91% 4.81%
34.38
6.31
-2.81% -6.58%
41.8B
3.7B
-8.04% 6.78%
49.44
11.41
8.72% 24.44%
14.4B
9.3B
0.17% -8.78%
16.85
1.56
-6.38% -9.73%
13.2B
2.5B
20.21% 12.42%
-64.89
5.3
19.93% 67.26%
12.6B
4.1B
-6.74% 22.26%
26.65
3.06
3.86% -2.39%
12.4B
1.9B
-1.22% 112.35%
43.79
6.57
29.17% 15.26%
11.7B
1.1B
6.51% 89.02%
-26.86
10.79
31.99% 20.63%
MID-CAP
2.8B
929.2M
-18.47% -23.42%
1.8K
3.03
28.93% 111.61%
2.3B
563.9M
0.16% -23.76%
-4.74
4.03
25.45% 26.76%
SMALL-CAP
474.3M
280.3M
-16.88% 6.76%
-2.49
1.69
-12.89% -148.37%
85.8M
31.2M
-0.82% -86.34%
-0.97
2.75
5.03% -1.81%
39.7M
9.2M
-12.02% -43.01%
-2.38
4.34
11.85% 44.12%
6.5M
9.0M
-28.30% -64.49%
-0.89
0.72
-53.31% 2.21%
183.8K
25.9M
-50.00% -94.83%
-0.01
0.01
-57.78% -93.11%

Medpace Holdings Inc News

Latest updates
Defense World55 minutes ago

Medpace Holdings Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue1.2%498492461434394384351331309296278260260230205231230216214201192
Costs and Expenses0.9%411408382348318306291267254242236212205184175195194186179175161
  S&GA Expenses2.7%43.0041.0039.0038.0033.0035.0033.0029.0028.0028.0027.0026.0022.0023.0022.0025.0021.0029.0024.0021.0021.00
EBITDA Margin-0.19*-0.20*0.21*0.21*0.21*0.20*0.19*0.19*0.20*0.20*0.20*0.19*--------
Income Taxes-1.9%12.0013.0015.0013.005.0016.0013.004.006.006.003.005.004.006.006.008.006.005.007.005.007.00
Earnings Before Taxes9.0%91.0083.0076.0086.0074.0082.0062.0065.0056.0055.0043.0049.0055.0047.0030.0036.0036.0029.0034.0025.0029.00
EBT Margin-0.5%0.18*0.18*0.19*0.19*0.19*0.19*0.19*0.18*0.18*0.18*0.19*0.19*---------
Net Income11.0%78.0071.0061.0073.0069.0066.0049.0061.0050.0049.0040.0043.0051.0041.0024.0029.0030.0024.0027.0019.0023.00
Net Income Margin-2.2%0.15*0.15*0.16*0.16*0.17*0.16*0.16*0.16*0.16*0.17*0.17*0.17*---------
Free Cashflow38.5%14610674.0071.0012710185.0037.0062.0066.0057.0051.00---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets11.4%1,6571,4871,4071,3961,3521,3281,3151,3441,6601,5771,4701,4511,3911,2961,2221,1381,1431,0721,0171,0071,005
  Current Assets32.3%594449379368334338329356691641550533474395319303317250194182178
    Cash Equivalents157.8%24595.0039.0047.0028.0031.0043.0083.0046139833933327821916113413279.0020.0030.0023.00
  Net PPE5.1%12111511511411010510499.0093.0088.0086.0085.0085.0071.0066.0050.0047.0044.0040.0038.0038.00
  Goodwill0%662662662662662662662662662662662662662662662662662662662662661
Liabilities8.1%1,0981,0161,0161,0489669791,032739707679618592585505484420417380359385406
  Current Liabilities9.0%925849852882803821879579557517473447440358338339343314296265263
  Short Term Borrowings---55.0011550.00140250--------------
  Long Term Debt--------------------56.0080.00
    LT Debt, Current----------------------
    LT Debt, Non Current--------------------56.0080.00
Shareholder's Equity18.7%559471391347386350283605953898852859806792738718726692658622599
  Retained Earnings26.2%-221-300-371-408-359-380-446-12023518514215911511270.0054.0068.0038.0014.00-13.14-32.33
  Additional Paid-In Capital0.8%803796785779771760753746728722717708696688677673667663652643639
Shares Outstanding0.2%31.0031.0031.0031.0031.0031.0032.0035.0036.0036.0036.0036.00---------
Float---5,600---3,700---5,100---2,500---1,800--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations36.7%156,395114,38582,51880,076136,684108,49196,61946,25670,89472,35362,76157,319105,49859,76344,26749,14856,94064,29246,63034,00539,442
  Share Based Compensation3.2%5,1655,0074,9065,4385,5935,7945,6534,3723,9814,0473,5702,8712,9612,7622,6165,4452,7079,4665,3853,1832,113
Cashflow From Investing7.7%-7,997-8,662-8,467-9,503-9,220-7,187-11,127-11,208-9,116-6,600-5,997-9,651-7,734-8,643-9,315-5,522-5,730-6,132-3,440-3,842-4,212
Cashflow From Financing103.1%1,523-49,272-82,210-52,683-131,121-109,108-123,463-412,0832,431-5,207-50,7799,102-40,2086,777-8,406-40,4458341,795-53,519-23,028-33,847
  Buy Backs100.0%--48523,992120,99847,182-374,717425,950-5,93956,157-47,447-7,58943,238-----

MEDP Income Statement

2023-12-31
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenue, net (includes $59.6 million, $55.4 million and $34.5 million with related parties for the years ended December 31, 2023, 2022 and 2021, respectively)$ 1,885,842$ 1,459,996$ 1,142,377
Operating expenses:   
Direct operating costs1,361,3371,027,558814,222
Selling, general and administrative161,352131,400108,421
Depreciation24,12918,98916,005
Amortization2,1993,3525,114
Total operating expenses1,549,0171,181,299943,762
Income from operations336,825278,697198,615
Other (expense) income, net:   
Miscellaneous (expense) income, net(655)7,0683,342
Interest expense, net(488)(2,905)(105)
Total other (expense) income, net(1,143)4,1633,237
Income before income taxes335,682282,860201,852
Income tax provision52,87237,49220,004
Net income$ 282,810$ 245,368$ 181,848
Net income per share attributable to common shareholders:   
Earnings per share, basic (in dollars per share)$ 9.20$ 7.57$ 5.06
Earnings per share, diluted (in dollars per share)$ 8.88$ 7.28$ 4.81
Weighted average common shares outstanding:   
Weighted average number of shares outstanding, basic (in shares)30,72232,38835,862
Weighted-average shares outstanding, diluted (in shares)31,84133,67137,697
Direct Costs   
Operating expenses:   
Direct operating costs$ 638,249$ 534,887$ 441,090
Reimbursed out-of-pocket expenses   
Operating expenses:   
Direct operating costs$ 723,088$ 492,671$ 373,132

MEDP Balance Sheet

2023-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 245,449$ 28,265
Accounts receivable and unbilled, net (includes $2.4 million and $7.7 million with related parties at December 31, 2023 and 2022, respectively)298,400253,404
Prepaid expenses and other current assets (includes $0.3 million with related parties at December 31, 2023)49,97952,293
Total current assets593,828333,962
Property and equipment, net120,589109,849
Operating lease right-of-use assets144,801139,068
Goodwill662,396662,396
Intangible assets, net35,80938,008
Deferred income taxes74,43548,083
Other assets24,97021,129
Total assets1,656,8281,352,495
Current liabilities:  
Accounts payable (includes $3.1 million and $0.3 million with related parties at December 31, 2023 and 2022, respectively)31,86933,069
Accrued expenses292,961210,125
Advanced billings (includes $10.1 million and $8.8 million with related parties at December 31, 2023 and 2022, respectively)559,860462,729
Short-term debt050,000
Other current liabilities (includes $12.5 million with related parties at December 31, 2022)40,44147,547
Total current liabilities925,131803,470
Operating lease liabilities142,122138,867
Deferred income tax liability2,4041,070
Other long-term liabilities28,22122,701
Total liabilities1,097,878966,108
Commitments and contingencies (see Note 12)
Shareholders’ equity:  
Preferred stock - $0.01 par-value; 5,000,000 shares authorized; no shares issued and outstanding at December 31, 2023 and 2022, respectively00
Common stock - $0.01 par-value; 250,000,000 shares authorized at December 31, 2023 and 2022, respectively; 30,752,292 and 31,091,694 shares issued and outstanding at December 31, 2023 and 2022, respectively308309
Treasury stock - 70,573 and 71,573 shares at December 31, 2023 and 2022, respectively(12,322)(12,497)
Additional paid-in capital802,681770,794
Accumulated deficit(221,645)(359,827)
Accumulated other comprehensive loss(10,072)(12,392)
Total shareholders’ equity558,950386,387
Total liabilities and shareholders’ equity$ 1,656,828$ 1,352,495
MEDP
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
 CEO
 WEBSITEmedpace.com
 INDUSTRYDiagnostics & Research
 EMPLOYEES5600

Medpace Holdings Inc Frequently Asked Questions


What is the ticker symbol for Medpace Holdings Inc? What does MEDP stand for in stocks?

MEDP is the stock ticker symbol of Medpace Holdings Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Medpace Holdings Inc (MEDP)?

As of Thu Apr 11 2024, market cap of Medpace Holdings Inc is 12.38 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MEDP stock?

You can check MEDP's fair value in chart for subscribers.

What is the fair value of MEDP stock?

You can check MEDP's fair value in chart for subscribers. The fair value of Medpace Holdings Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Medpace Holdings Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MEDP so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Medpace Holdings Inc a good stock to buy?

The fair value guage provides a quick view whether MEDP is over valued or under valued. Whether Medpace Holdings Inc is cheap or expensive depends on the assumptions which impact Medpace Holdings Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MEDP.

What is Medpace Holdings Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 11 2024, MEDP's PE ratio (Price to Earnings) is 43.79 and Price to Sales (PS) ratio is 6.57. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MEDP PE ratio will change depending on the future growth rate expectations of investors.